Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.

被引：42

作者：

Hatake K. ^{[1
]}

Tokudome N. ^{[1
]}

Ito Y. ^{[1
]}

机构：

[1] Division of Medical Oncology, Cancer Institute Hospital, Tokyo

来源：

Breast Cancer | 2007年 / 14卷 / 2期

关键词：

Molecular targeting drug; Trastuzumab; Lapatinib; Erlotinib; Bevacituzumab;

D O I：

10.2325/jbcs.977

中图分类号：

学科分类号：

摘要：

Here we reviewed the recent progress of molecular targeting drugs, including trastuzumab, lapatinib, erlotinib and bevacituzumab. Fortunately, Her-2 positive cases of metastatic or relapsed cases, those with the worse prognosis, are responsive to trastuzumab-based chemotherapy. Lapatinib will likely be effective against trastuzumab-resistant cases and brain metastases. Furthermore, the introduction of bevacituzumab will improve VEGF-VEGFR- associated tumor growth.

引用

页码：132 / 149

页数：17

共 397 条

[1]

Christensen LA(2006)(Targeting oncogenes to improve breast cancer chemotherapy) Cancer Res 66 4089-4094

[2]

Finch RA(2006)Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions Drugs 66 1577-1591

[3]

Booker AJ(2006)(High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer) Breast Cancer 13 172-178

[4]

Vasquez KM(2006)(Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer) J Clin Oncol 24 5658-5663

[5]

Bernard-Marty C(2004)(Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer) Tumori 90 40-43

[6]

Lebrun F(2006)Related Articles, Links Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience Breast Cancer 13 329-333

[7]

Awada A(2005)Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology Ann Oncol 4 iv7-iv13

[8]

Piccart MJ(2006)(Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts) Clin Cancer Res 12 904-916

[9]

Sawaki M(2005)(HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kipl via multiple signaling pathways) Cell Cycle 4 87-95

[10]

Ito Y(2005)Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells Med Hypotheses 64 997-1001

← 1 2 3 4 5 6 7 8 9 10 →